BDNF Val66Met moderates memory impairment, hippocampal function and tau in preclinical autosomal dominant Alzheimer's disease

Yen Ying Lim, Jason Hassenstab, Carlos Cruchaga, Alison Goate, Anne M. Fagan, Tammie L S Benzinger, Paul Maruff, Peter J. Snyder, Colin L. Masters, Ricardo Allegri, Jasmeer Chhatwal, Martin Farlow, Neill R. Graff-Radford, Christoph Laske, Johannes Levin, Eric McDade, John M. Ringman, Martin Rossor, Stephen Salloway, Peter R. Schofield & 3 others David M. Holtzman, John C. Morris, Randall J. Bateman

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

See Rogaeva and Schmitt-Ulms (doi:10.1093/aww201) for a scientific commentary on this article. The brain-derived neurotrophic factor (BDNF) Val66Met polymorphism is implicated in synaptic excitation and neuronal integrity, and has previously been shown to moderate amyloid-β-related memory decline and hippocampal atrophy in preclinical sporadic Alzheimer's disease. However, the effect of BDNF in autosomal dominant Alzheimer's disease is unknown. We aimed to determine the effect of BDNF Val66Met on cognitive function, hippocampal function, tau and amyloid-β in preclinical autosomal dominant Alzheimer's disease. We explored effects of apolipoprotein E (APOE) ϵ4 on these relationships. The Dominantly Inherited Alzheimer Network conducted clinical, neuropsychological, genetic, biomarker and neuroimaging measures at baseline in 131 mutation non-carriers and 143 preclinical autosomal dominant Alzheimer's disease mutation carriers on average 12 years before clinical symptom onset. BDNF genotype data were obtained for mutation carriers (95 Val66 homozygotes, 48 Met66 carriers). Among preclinical mutation carriers, Met66 carriers had worse memory performance, lower hippocampal glucose metabolism and increased levels of cerebrospinal fluid tau and phosphorylated tau (p-tau) than Val66 homozygotes. Cortical amyloid-β and cerebrospinal fluid amyloid-β42 levels were significantly different from non-carriers but did not differ between preclinical mutation carrier Val66 homozygotes and Met66 carriers. There was an effect of APOE on amyloid-β levels, but not cognitive function, glucose metabolism or tau. As in sporadic Alzheimer's disease, the deleterious effects of amyloid-β on memory, hippocampal function, and tau in preclinical autosomal dominant Alzheimer's disease mutation carriers are greater in Met66 carriers. To date, this is the only genetic factor found to moderate downstream effects of amyloid-β in autosomal dominant Alzheimer's disease.

Original languageEnglish (US)
Pages (from-to)2766-2777
Number of pages12
JournalBrain
Volume139
Issue number10
DOIs
StatePublished - Oct 1 2016

Fingerprint

Brain-Derived Neurotrophic Factor
Amyloid
Alzheimer Disease
Mutation
Homozygote
Cognition
Cerebrospinal Fluid
Apolipoprotein E4
Glucose
Apolipoproteins E
Alzheimer's Disease
Carrier
Impairment
Neuroimaging
Atrophy
Biomarkers
Genotype

Keywords

  • Alzheimer's disease
  • amyloid-β
  • dementia
  • genetics
  • tau

ASJC Scopus subject areas

  • Medicine(all)
  • Arts and Humanities (miscellaneous)
  • Clinical Neurology

Cite this

Lim, Y. Y., Hassenstab, J., Cruchaga, C., Goate, A., Fagan, A. M., Benzinger, T. L. S., ... Bateman, R. J. (2016). BDNF Val66Met moderates memory impairment, hippocampal function and tau in preclinical autosomal dominant Alzheimer's disease. Brain, 139(10), 2766-2777. https://doi.org/10.1093/brain/aww200

BDNF Val66Met moderates memory impairment, hippocampal function and tau in preclinical autosomal dominant Alzheimer's disease. / Lim, Yen Ying; Hassenstab, Jason; Cruchaga, Carlos; Goate, Alison; Fagan, Anne M.; Benzinger, Tammie L S; Maruff, Paul; Snyder, Peter J.; Masters, Colin L.; Allegri, Ricardo; Chhatwal, Jasmeer; Farlow, Martin; Graff-Radford, Neill R.; Laske, Christoph; Levin, Johannes; McDade, Eric; Ringman, John M.; Rossor, Martin; Salloway, Stephen; Schofield, Peter R.; Holtzman, David M.; Morris, John C.; Bateman, Randall J.

In: Brain, Vol. 139, No. 10, 01.10.2016, p. 2766-2777.

Research output: Contribution to journalArticle

Lim, YY, Hassenstab, J, Cruchaga, C, Goate, A, Fagan, AM, Benzinger, TLS, Maruff, P, Snyder, PJ, Masters, CL, Allegri, R, Chhatwal, J, Farlow, M, Graff-Radford, NR, Laske, C, Levin, J, McDade, E, Ringman, JM, Rossor, M, Salloway, S, Schofield, PR, Holtzman, DM, Morris, JC & Bateman, RJ 2016, 'BDNF Val66Met moderates memory impairment, hippocampal function and tau in preclinical autosomal dominant Alzheimer's disease', Brain, vol. 139, no. 10, pp. 2766-2777. https://doi.org/10.1093/brain/aww200
Lim, Yen Ying ; Hassenstab, Jason ; Cruchaga, Carlos ; Goate, Alison ; Fagan, Anne M. ; Benzinger, Tammie L S ; Maruff, Paul ; Snyder, Peter J. ; Masters, Colin L. ; Allegri, Ricardo ; Chhatwal, Jasmeer ; Farlow, Martin ; Graff-Radford, Neill R. ; Laske, Christoph ; Levin, Johannes ; McDade, Eric ; Ringman, John M. ; Rossor, Martin ; Salloway, Stephen ; Schofield, Peter R. ; Holtzman, David M. ; Morris, John C. ; Bateman, Randall J. / BDNF Val66Met moderates memory impairment, hippocampal function and tau in preclinical autosomal dominant Alzheimer's disease. In: Brain. 2016 ; Vol. 139, No. 10. pp. 2766-2777.
@article{463280c1f63d43bc9e04fdae8f0272c7,
title = "BDNF Val66Met moderates memory impairment, hippocampal function and tau in preclinical autosomal dominant Alzheimer's disease",
abstract = "See Rogaeva and Schmitt-Ulms (doi:10.1093/aww201) for a scientific commentary on this article. The brain-derived neurotrophic factor (BDNF) Val66Met polymorphism is implicated in synaptic excitation and neuronal integrity, and has previously been shown to moderate amyloid-β-related memory decline and hippocampal atrophy in preclinical sporadic Alzheimer's disease. However, the effect of BDNF in autosomal dominant Alzheimer's disease is unknown. We aimed to determine the effect of BDNF Val66Met on cognitive function, hippocampal function, tau and amyloid-β in preclinical autosomal dominant Alzheimer's disease. We explored effects of apolipoprotein E (APOE) ϵ4 on these relationships. The Dominantly Inherited Alzheimer Network conducted clinical, neuropsychological, genetic, biomarker and neuroimaging measures at baseline in 131 mutation non-carriers and 143 preclinical autosomal dominant Alzheimer's disease mutation carriers on average 12 years before clinical symptom onset. BDNF genotype data were obtained for mutation carriers (95 Val66 homozygotes, 48 Met66 carriers). Among preclinical mutation carriers, Met66 carriers had worse memory performance, lower hippocampal glucose metabolism and increased levels of cerebrospinal fluid tau and phosphorylated tau (p-tau) than Val66 homozygotes. Cortical amyloid-β and cerebrospinal fluid amyloid-β42 levels were significantly different from non-carriers but did not differ between preclinical mutation carrier Val66 homozygotes and Met66 carriers. There was an effect of APOE on amyloid-β levels, but not cognitive function, glucose metabolism or tau. As in sporadic Alzheimer's disease, the deleterious effects of amyloid-β on memory, hippocampal function, and tau in preclinical autosomal dominant Alzheimer's disease mutation carriers are greater in Met66 carriers. To date, this is the only genetic factor found to moderate downstream effects of amyloid-β in autosomal dominant Alzheimer's disease.",
keywords = "Alzheimer's disease, amyloid-β, dementia, genetics, tau",
author = "Lim, {Yen Ying} and Jason Hassenstab and Carlos Cruchaga and Alison Goate and Fagan, {Anne M.} and Benzinger, {Tammie L S} and Paul Maruff and Snyder, {Peter J.} and Masters, {Colin L.} and Ricardo Allegri and Jasmeer Chhatwal and Martin Farlow and Graff-Radford, {Neill R.} and Christoph Laske and Johannes Levin and Eric McDade and Ringman, {John M.} and Martin Rossor and Stephen Salloway and Schofield, {Peter R.} and Holtzman, {David M.} and Morris, {John C.} and Bateman, {Randall J.}",
year = "2016",
month = "10",
day = "1",
doi = "10.1093/brain/aww200",
language = "English (US)",
volume = "139",
pages = "2766--2777",
journal = "Brain",
issn = "0006-8950",
publisher = "Oxford University Press",
number = "10",

}

TY - JOUR

T1 - BDNF Val66Met moderates memory impairment, hippocampal function and tau in preclinical autosomal dominant Alzheimer's disease

AU - Lim, Yen Ying

AU - Hassenstab, Jason

AU - Cruchaga, Carlos

AU - Goate, Alison

AU - Fagan, Anne M.

AU - Benzinger, Tammie L S

AU - Maruff, Paul

AU - Snyder, Peter J.

AU - Masters, Colin L.

AU - Allegri, Ricardo

AU - Chhatwal, Jasmeer

AU - Farlow, Martin

AU - Graff-Radford, Neill R.

AU - Laske, Christoph

AU - Levin, Johannes

AU - McDade, Eric

AU - Ringman, John M.

AU - Rossor, Martin

AU - Salloway, Stephen

AU - Schofield, Peter R.

AU - Holtzman, David M.

AU - Morris, John C.

AU - Bateman, Randall J.

PY - 2016/10/1

Y1 - 2016/10/1

N2 - See Rogaeva and Schmitt-Ulms (doi:10.1093/aww201) for a scientific commentary on this article. The brain-derived neurotrophic factor (BDNF) Val66Met polymorphism is implicated in synaptic excitation and neuronal integrity, and has previously been shown to moderate amyloid-β-related memory decline and hippocampal atrophy in preclinical sporadic Alzheimer's disease. However, the effect of BDNF in autosomal dominant Alzheimer's disease is unknown. We aimed to determine the effect of BDNF Val66Met on cognitive function, hippocampal function, tau and amyloid-β in preclinical autosomal dominant Alzheimer's disease. We explored effects of apolipoprotein E (APOE) ϵ4 on these relationships. The Dominantly Inherited Alzheimer Network conducted clinical, neuropsychological, genetic, biomarker and neuroimaging measures at baseline in 131 mutation non-carriers and 143 preclinical autosomal dominant Alzheimer's disease mutation carriers on average 12 years before clinical symptom onset. BDNF genotype data were obtained for mutation carriers (95 Val66 homozygotes, 48 Met66 carriers). Among preclinical mutation carriers, Met66 carriers had worse memory performance, lower hippocampal glucose metabolism and increased levels of cerebrospinal fluid tau and phosphorylated tau (p-tau) than Val66 homozygotes. Cortical amyloid-β and cerebrospinal fluid amyloid-β42 levels were significantly different from non-carriers but did not differ between preclinical mutation carrier Val66 homozygotes and Met66 carriers. There was an effect of APOE on amyloid-β levels, but not cognitive function, glucose metabolism or tau. As in sporadic Alzheimer's disease, the deleterious effects of amyloid-β on memory, hippocampal function, and tau in preclinical autosomal dominant Alzheimer's disease mutation carriers are greater in Met66 carriers. To date, this is the only genetic factor found to moderate downstream effects of amyloid-β in autosomal dominant Alzheimer's disease.

AB - See Rogaeva and Schmitt-Ulms (doi:10.1093/aww201) for a scientific commentary on this article. The brain-derived neurotrophic factor (BDNF) Val66Met polymorphism is implicated in synaptic excitation and neuronal integrity, and has previously been shown to moderate amyloid-β-related memory decline and hippocampal atrophy in preclinical sporadic Alzheimer's disease. However, the effect of BDNF in autosomal dominant Alzheimer's disease is unknown. We aimed to determine the effect of BDNF Val66Met on cognitive function, hippocampal function, tau and amyloid-β in preclinical autosomal dominant Alzheimer's disease. We explored effects of apolipoprotein E (APOE) ϵ4 on these relationships. The Dominantly Inherited Alzheimer Network conducted clinical, neuropsychological, genetic, biomarker and neuroimaging measures at baseline in 131 mutation non-carriers and 143 preclinical autosomal dominant Alzheimer's disease mutation carriers on average 12 years before clinical symptom onset. BDNF genotype data were obtained for mutation carriers (95 Val66 homozygotes, 48 Met66 carriers). Among preclinical mutation carriers, Met66 carriers had worse memory performance, lower hippocampal glucose metabolism and increased levels of cerebrospinal fluid tau and phosphorylated tau (p-tau) than Val66 homozygotes. Cortical amyloid-β and cerebrospinal fluid amyloid-β42 levels were significantly different from non-carriers but did not differ between preclinical mutation carrier Val66 homozygotes and Met66 carriers. There was an effect of APOE on amyloid-β levels, but not cognitive function, glucose metabolism or tau. As in sporadic Alzheimer's disease, the deleterious effects of amyloid-β on memory, hippocampal function, and tau in preclinical autosomal dominant Alzheimer's disease mutation carriers are greater in Met66 carriers. To date, this is the only genetic factor found to moderate downstream effects of amyloid-β in autosomal dominant Alzheimer's disease.

KW - Alzheimer's disease

KW - amyloid-β

KW - dementia

KW - genetics

KW - tau

UR - http://www.scopus.com/inward/record.url?scp=84991038728&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84991038728&partnerID=8YFLogxK

U2 - 10.1093/brain/aww200

DO - 10.1093/brain/aww200

M3 - Article

VL - 139

SP - 2766

EP - 2777

JO - Brain

JF - Brain

SN - 0006-8950

IS - 10

ER -